AzurRx BioPharma - Home
 Clinical Trial Indication #Patients Highlights
Phase 2 Safety and Efficacy Trial

reservoir
ClinicalTrials.gov: NCT04858425 
COVID-19 GI Infections 148
  • First study towards repurposing potent anti-viral therapeutic to treat gastrointestinal infections of COVID-19
  • Proprietary oral formulation of niclosamide